Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Galapagos ADR Representing Ord Shs GLPG

Healthcare Biotechnology
Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company focuses on developing a portfolio of... see more

Recent & Breaking News (NDAQ:GLPG)

Galapagos to present progress in CF programs at NACFC 2016

GlobeNewswire October 27, 2016

16 Stocks Moving In Tuesday's Pre-Market Session

Benzinga.com  October 18, 2016

Transparency notification - FMR LLC reaches 10% threshold

GlobeNewswire October 12, 2016

MorphoSys and Galapagos Start First-In-Patient Dosing of IL-17C Antibody MOR106 in Atopic Dermatitis

GlobeNewswire September 29, 2016

Successful completion of regulatory consultations to progress filgotinib to Phase 3 in inflammatory bowel disease

GlobeNewswire September 27, 2016

Endoscopic improvements with filgotinib are consistent with clinical remission rates in patients with Crohn's disease

GlobeNewswire September 25, 2016

Galapagos increases share capital through warrant exercises

GlobeNewswire September 19, 2016

Benzinga's Volume Movers

Benzinga.com  September 15, 2016

Janney Initiates Galapagos At Buy, Sees Fair Value Of Shares At $64

Benzinga.com  August 30, 2016

FINCH filgotinib Phase 3 program initiated in rheumatoid arthritis

GlobeNewswire August 22, 2016

Galapagos receives transparency notification from Federated

GlobeNewswire July 29, 2016

Focus on filgotinib and cystic fibrosis

GlobeNewswire July 28, 2016

Invitation to the Special and Extraordinary Shareholders' Meetings of 26 July 2016 - Nomination of Mary Kerr for Galapagos' Board of Directors

GlobeNewswire June 23, 2016

MDxHealth Contracts with Priority Health for Coverage of ConfirmMDx

GlobeNewswire June 23, 2016

Galapagos' R&D Update 2016

GlobeNewswire June 15, 2016

Galapagos selected for AEX Index

GlobeNewswire June 9, 2016

Galapagos creates new warrant plan

GlobeNewswire June 1, 2016

Guggenheim Energy & Income Fund Announces Quarterly Distribution

GlobeNewswire June 1, 2016